© Reuters. Diabetes drug Farxiga (dapagliflozin) is displayed at a pharmacy in Provo
(Reuters) -AstraZeneca said on Monday primary data from a late-stage study to test whether its diabetes drug Farxiga could treat patients hospitalised with COVID-19, who are at risk of developing serious complications, did not meet its main goals.
The British drugmaker said Farxiga did not achieve statistical significance in cutting the risk of the disease worsening and death in such patients.
Farxiga was given over 30 days in a global trial of 1,250 patients hospitalised with COVID-19, in addition to the local standard of care.
Patients in the trial also had a medical history of hypertension, cardiovascular disease and heart failure, type-2 diabetes or chronic kidney disease.
AstraZeneca (NASDAQ:) said the safety and tolerability profile for Farxiga at 30 days in the trial was consistent with established safety profile of the medicine.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.